CRPOF News and Press, Ceapro Inc From 08/24/22

Ceapro press release ( OTCQX:CRPOF ): Q2 GAAP EPS of $0.02. Revenue of $5.5M (+25.0% Y/Y). For further details see: Ceapro GAAP EPS of $0.02, revenue of $5.5M

– Company boasts highest second quarter sales to date; Q2 2022 sales of $5,500,000 vs $4,409,000 in Q2 2021, a 25% increase – YTD Sales increased 28% vs 2021 – $11,672,000 vs $9,110,000 – Income before tax of $2,177,000 in Q2 2022 vs $676,...

– Continuation of research with McMaster University to validate the anti-fibrotic properties of the Company’s PGX-Processed yeast beta glucan in experimental models of lung fibrosis and to pave the way for Phase 1 clinical trial EDMONTON, Alberta, Aug. 11, 2022 (GLOB...

– PGX Technology continues to demonstrate the ability to generate superior novel bioactive delivery systems – Findings from the collaborative project with the University of Alberta illustrate how aerogels generated using the PGX Technology can be uniformly loaded w...

Recognized commercial leader with over 20 years of experience across diverse healthcare industries Appointment marks strategic step in driving Company towards next phase of growth EDMONTON, Alberta, July 12, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: ...

EDMONTON, Alberta, June 07, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and co...

EDMONTON, Alberta, May 23, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare...

Ceapro press release (OTCQX:CRPOF): Q1 GAAP EPS of $0.03. Revenue of $6.17M (+31.3% Y/Y). For further details see: Ceapro GAAP EPS of $0.03, revenue of $6.17M

– Best quarterly financial results in history of the Company – Q1 2022 sales of $6,172,000 vs $4,702,000 in Q1 2021, a 31% increase – Operating profit of $2,614,000 in Q1 2022 vs $515,000 in Q1 2021 – Company responds to increased ...

EDMONTON, Alberta, May 13, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare...